We focused on NSD3 for additional investigations in pancreatic cancers as we found that, compared to NSD1 and − 2, it was the most prominently expressed gene across NSD members, the most frequently altered NSD gene, and that it was also significantly correlated with cancer prognosis as well as immune infiltration in PAAD. This evidence concerns the gene NSD3 and familial pancreatic carcinoma.